Discovery Labs Initiates Launch of AFECTAIR®
First Phase of Launch Introduces New, Proprietary Technology to Select
Neonatal and Pediatric Critical Care Centers
WARRINGTON, Pa., Jan. 3, 2013
WARRINGTON, Pa., Jan. 3, 2013 /PRNewswire/ --Discovery Laboratories, Inc.
(NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new
standard in respiratory critical care, today announced it has initiated the
launch of its AFECTAIR^® airway connector for infants receiving aerosolized
medication in neonatal or pediatric intensive care units (NICU and PICU,
respectively). The AFECTAIR device simplifies the delivery of aerosolized
medication to critical care patients who require ventilatory support by
introducing the medication directly at the patient interface.
The launch begins with an AFECTAIR user experience program in leading U.S.
critical care centers that represent approximately ten percent of the
Company's targeted institutions. The selected institutions are considered to
be centers of influence within the neonatal and pediatric critical care
community. The initial phase of this launch is intended to facilitate
peer-to-peer exchange that will allow physicians and respiratory therapists to
discuss the advantages and proper utilization of this novel device. This
phase of the launch is anticipated to run through the first quarter of 2013 at
which time Discovery Labs will initiate a broader introduction of AFECTAIR.
"We are very excited to formally introduce AFECTAIR to the neonatal and
pediatric critical care community," said Thomas F. Miller, Chief Operating
Officer at Discovery Labs. "The AFECTAIR technology exemplifies Discovery
Labs' innovative spirit and progress toward advancing new standards in
respiratory critical care."
The AFECTAIR technology was developed as a component of the AEROSURF^®
development program and is a proprietary, disposable device that simplifies
the delivery of aerosolized medications to critical-care patients requiring
ventilatory support such as intermittent mechanical ventilation or continuous
positive airway pressure. To date, in vitro studies suggest that the
AFECTAIR technology may be an effective new solution for delivering
aerosolized medications to infants receiving ventilatory support while
providing healthcare professionals with a simplified alternative to current
practices. According to national health statistics and internal market
assessment data, it is estimated that each year approximately 355,000
pediatric patients in the United States are eligible to receive aerosolized
medications while requiring ventilator support.
Discovery Labs is also pursuing European Conformity (CE) marking for potential
commercialization of AFECTAIR for infants in the European Union (EU) in 2013.
AEROSURF (lucinactant for inhalation), Discovery Labs' initial aerosolized KL4
surfactant product, is under development to address respiratory distress
syndrome in premature infants. Through the effective delivery of aerosolized
KL4 surfactant using Discovery Labs' proprietary capillary aerosol generator
technology and AFECTAIR, AEROSURF may significantly expand the
surfactant-eligible treatment population by providing neonatologists with a
means of administering surfactant without the risks currently associated with
invasive endotracheal intubation and mechanical ventilation.
ABOUT DISCOVERY LABS
Discovery Laboratories, Inc. is a specialty biotechnology company with one
focus – to create life-saving products for patients with respiratory disease
and improve the standard of care for pulmonary medicine. Discovery Labs'
novel proprietary KL4 surfactant technology produces a synthetic,
peptide-containing surfactant that is structurally similar to pulmonary
surfactant and is being developed in liquid, lyophilized and aerosol dosage
forms. Discovery Labs is also developing its proprietary drug delivery
technologies to enable efficient, targeted upper respiratory or alveolar
delivery of aerosolized KL4 surfactant. Discovery Labs believes that its
proprietary technologies make it possible, for the first time, to develop a
significant pipeline of surfactant products to address a variety of
respiratory diseases for which there frequently are few or no approved
therapies. For more information, please visit our website at
To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from the
statements made. Examples of such risks and uncertainties, including those
related to the development and commercial introduction of AFECTAIR in the U.S.
and EU, are described in Discovery Labs' filings with the Securities and
Exchange Commission including the most recent reports on Forms 10-K, 10-Q and
8-K, and any amendments thereto. Any forward-looking statement in this release
speaks only as of the date on which it is made. The Company assumes no
obligation to update or revise any forward-looking statements.
SOURCE Discovery Laboratories, Inc.
Contact: Media Relations, Michael Parks, Pitch360, +1-484-356-7105,
Michael@pitch360inc.com, or Investor Relations, Michael Rice, LifeSci
Advisors, +1-646-597-6979, John G. Cooper, President and Chief Financial
Press spacebar to pause and continue. Press esc to stop.